| Systematic (IUPAC) name | |
|---|---|
| 2-(6-fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3,3-pentafluoropropoxy)benzyl)ethanamine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 467459-31-0 |
| ATC code | None |
| Synonyms | Lu-AE-58054 |
| Chemical data | |
| Formula | C20H19F5N2O |
| Mol. mass | 398.37 g/mol |
| |
|
Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of February 2010 it is in phase II clinical trials.[2]
|
|||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)